Neural checkpoint therapy in lung cancer

Area of Science:

• Oncology
• Neuroscience
• Immunology

Background:

• Sensory nerves are increasingly recognized as key regulators of the tumor microenvironment and immune responses.
• Lung adenocarcinoma (LUAD) often exhibits an "immune-cold" phenotype, characterized by limited immune cell infiltration and poor response to immunotherapy.
• Understanding the interplay between neural signaling and anti-tumor immunity is crucial for developing novel therapeutic strategies.

Purpose of the Study:

• To investigate the role of a specific sensory nerve pathway involving Nav1.8+ neurons and calcitonin gene-related peptide (CGRP) in LUAD.
• To elucidate how this neural axis influences tertiary lymphoid structure (TLS) formation and anti-tumor immunity in LUAD.
• To explore the potential of targeting this neural axis for enhancing immunotherapy efficacy in LUAD.

Main Methods:

• Utilized a combination of immunohistochemistry and molecular analyses to identify and characterize Nav1.8+ neurons and CGRP expression in LUAD tissues.
• Assessed the correlation between Nav1.8+/CGRP signaling and the presence/organization of TLS within the tumor microenvironment.
• Investigated the functional impact of this neural axis on immune cell infiltration and function using preclinical LUAD models.

Main Results:

• Identified a distinct Nav1.8+ neuron-CGRP signaling axis within the tumor microenvironment of LUAD.
• Demonstrated that this neural axis is associated with impaired TLS formation, leading to reduced immune cell infiltration.
• Showcased that blockade of this neural pathway can promote immune cell infiltration and remodel the immune-cold tumor microenvironment.

Conclusions:

• The Nav1.8+ neuron-CGRP axis represents a novel mechanism by which sensory nerves suppress anti-tumor immunity in LUAD.
• Targeting this neural pathway, potentially through neural checkpoint blockade, offers a promising strategy to enhance immunotherapy responses in immune-cold tumors.
• Further research into neuro-immune interactions in cancer holds significant potential for advancing oncological therapies.